Procore Technologies, Inc. (NYSE: PCOR), a leading technology partner for every stage of construction, today announced investments in its Building Information Modeling (BIM) capabilities. Expanding on its existing BIM offerings, Procore has announced its acquisitions of Novorender and FlyPaper, which upon integration will empower owners and contractors worldwide to unlock BIM, streamline coordination, and connect critical BIM data seamlessly across the Procore platform. In recent years, BIM ad...

CCIC Europe Food Test Co., Ltd. (CCIC EFT) is stepping up efforts to help more European companies access China’s infant formula market. On June 25–26, CCIC EFT will host a targeted seminar in Wageningen, the Netherlands, focused on regulatory updates and market access for producers of infant formula, older infant and toddler milk-based formula, and food for special medical purposes (FSMP). This press release features multimedia. View the full release here: https:/...

Black & Veatch, a global leader in human critical infrastructure solutions, will share ways to adapt international best practices to accelerate Southeast Asia’s energy transition at the Energy Asia 2025 conference, taking place June 16-18 at the Kuala Lumpur Convention Center here. “As geopolitical tensions rise and extreme heat waves become more prolonged, Malaysia and its Southeast Asian neighbors need energy transition solutions that will meet their economic and environmental targets. ...

Onboard Dynamics LLC (“Onboard Dynamics”), a leading developer of pipeline evacuation technology, has entered into a strategic partnership with T.D. Williamson (“TDW”), a global provider of pipeline services and equipment. This collaboration will enable TDW to represent, market, and sell Onboard Dynamics’ products and services directly to customers across the Eastern Hemisphere through its own network of channel partners. This press release features multimedia. Vi...

Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients wit...